<DOC>
	<DOCNO>NCT00880763</DOCNO>
	<brief_summary>The study evaluate safety efficacy vaniprevir ( MK7009 ) , administer Pegylated-Interferon ( peg-IFN ) Ribavirin , Japanese patient Hepatitis C infection . The primary hypothesis 1 . ) proportion patient achieve rapid viral response ( RVR ) one vaniprevir treatment group superior placebo group , administer concomitantly pegylated interferon ( peg-IFN ) α-2a ribavirin ; 2 . ) vaniprevir study dos well tolerate compare placebo , administer concomitantly peg-IFN α-2a ribavirin 28 day .</brief_summary>
	<brief_title>A Study Safety Efficacy Vaniprevir Administered With Pegylated-Interferon Ribavirin Japanese Participants With Chronic Hepatitis C Infection ( 7009-016 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Has chronic genotype 1 Hepatitis C infection Has tolerate previous course pegIFN ribavirin Has HIV Has Hepatitis B Has history clinically significant medical condition may interfere study ( e.g. , stroke chronic seizure major neurological disorder ) contraindicate treatment pegIFN ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>